Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia
Launched by HOSPITAL UNIVERSITARI DE BELLVITGE · Feb 24, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of a medication called intravenous lacosamide for treating sudden, severe pain caused by trigeminal neuralgia, a condition that affects the facial nerves. The trial is taking place at the Hospital de Bellvitge and is currently looking for participants. If you or someone you know has been diagnosed with trigeminal neuralgia and is experiencing a sudden flare-up of pain, you might be eligible to join the study. To qualify, participants need to be over 18 years old and must give their consent to take part in the trial.
If you decide to participate, you will receive intravenous lacosamide as part of your treatment plan in the emergency department. The goal of the study is to see how well this medication helps relieve your pain and to monitor any side effects. It’s important to note that individuals with certain medical conditions or those who have had specific allergic reactions to lacosamide will not be able to join the study. This trial aims to provide valuable information that could improve pain management for people with trigeminal neuralgia in the future.
Gender
ALL
Eligibility criteria
- • All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion.
- Inclusion Criteria:
- • Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3).
- • Age over 18 years.
- • Signed informed consent.
- Exclusion Criteria:
- • Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block).
- • Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent.
- • Language barrier.
- • Lack of cooperation.
About Hospital Universitari De Bellvitge
Hospital Universitari de Bellvitge is a leading academic medical center located in L'Hospitalet de Llobregat, Spain, affiliated with the University of Barcelona. Renowned for its commitment to advanced patient care, innovative research, and education, the hospital plays a pivotal role in the development and execution of clinical trials across various therapeutic areas. With a multidisciplinary team of healthcare professionals and researchers, Hospital Universitari de Bellvitge strives to enhance medical knowledge and improve treatment outcomes through rigorous scientific inquiry and collaboration. Its state-of-the-art facilities and comprehensive patient care services make it an ideal environment for conducting high-quality clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
L'hospitalet De Llobregat, Barcelona, Spain
Patients applied
Trial Officials
Albert Muñoz Vendrell, PhD
Principal Investigator
Hospital Universitari de Bellvitge
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported